Search hospitals > Indiana > Indianapolis
Dawes Fretzin Clinical Research Group, LLC
Claim this profileIndianapolis, Indiana 46250
Global Leader in Psoriasis
Global Leader in Atopic Dermatitis
Conducts research for Eczema
Conducts research for Plaque Psoriasis
Conducts research for Alopecia Areata
141 reported clinical trials
4 medical researchers
Summary
Dawes Fretzin Clinical Research Group, LLC is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Psoriasis, Atopic Dermatitis, Eczema, Plaque Psoriasis, Alopecia Areata and other specialties. Dawes Fretzin Clinical Research Group, LLC is involved with conducting 141 clinical trials across 72 conditions. There are 4 research doctors associated with this hospital, such as Scott Fretzin, Kenneth W Dawes, Scott Alfred Fretzin, and John S Barbieri, MD, MBA.Top PIs
Scott FretzinDawes Fretzin Clinical Research Group, LLC2 years of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Hidradenitis Suppurativa
15 reported clinical trials
21 drugs studied
Kenneth W DawesDawes Fretzin Clinical Research Group, LLC3 years of reported clinical research
Studies Atopic Dermatitis
Studies Eczema
8 reported clinical trials
13 drugs studied
Scott Alfred FretzinDawes Fretzin Clinical Research Group, LLC1 year of reported clinical research
Studies Atopic Dermatitis
Studies Eczema
3 reported clinical trials
2 drugs studied
John S Barbieri, MD, MBAPenn State University (Hershey Medical Center)2 years of reported clinical research
Studies Acne
1 reported clinical trial
2 drugs studied
Clinical Trials running at Dawes Fretzin Clinical Research Group, LLC
Atopic Dermatitis
Eczema
Hidradenitis Suppurativa
Vitiligo
Alopecia Areata
Psoriasis
Systemic Lupus Erythematosus
Cutaneous Lupus Erythematosus
Sleep Disorders
Acne
Ruxolitinib Cream
for Atopic Dermatitis/Eczema
This trial is testing a skin cream called ruxolitinib to see if it can help people with Atopic Dermatitis sleep better by reducing inflammation and itching. Ruxolitinib cream is used to treat inflammatory skin diseases like atopic dermatitis.
Recruiting3 awards Phase 48 criteria
Amlitelimab + Topical Corticosteroids
for Atopic Dermatitis (AQUA)
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 [RIVER-AD] study).
Recruiting1 award Phase 35 criteria
Ruxolitinib Cream
for Prurigo
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
Recruiting1 award Phase 1
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Dawes Fretzin Clinical Research Group, LLC?
Dawes Fretzin Clinical Research Group, LLC is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Psoriasis, Atopic Dermatitis, Eczema, Plaque Psoriasis, Alopecia Areata and other specialties. Dawes Fretzin Clinical Research Group, LLC is involved with conducting 141 clinical trials across 72 conditions. There are 4 research doctors associated with this hospital, such as Scott Fretzin, Kenneth W Dawes, Scott Alfred Fretzin, and John S Barbieri, MD, MBA.